Exploratory secondary analysis of the ABCD trial (dexamethasone vs placebo for dyspnoea) in 45 patients with cancer: in the placebo group, higher baseline cytokine levels were negatively associated with placebo response across multiple symptoms (33/40 combinations at day 7).
Secondary analysisn = 45
Hui et al. Predictive biomarkers of placebo response in patients with cancer: an exploratory analysis of the ABCD randomized clinical trial